Oppenheimer & Co.

Oppenheimer reiterates its Outperform on Nvidia (NASDAQ: NVDA) as the company is purported to be in joint venture talks with Foxconn for a research and development center in China. Oppenheimer notes, "Foxconn Electronics (Hon Hai Precision Industry) and Nvidia, under coordination with the Tianjin...

In a recent research note, Oppenheimer reiterates its Outperform rating on Apple (NASDAQ: AAPL) as news sources indicate the company could launch a smaller version of its popular iPad tablet in 2012. Oppenheimer notes a Digitimes report saying: "Apple is likely to launch a 7.85-inch iPad prior to...

Oppenheimer raises its rating on Linear Technology (NASDAQ: LLTC) to Outperform from Perform and established a price target of $36 per share as the company is expected to benefit disproportionately from demand inflection. Oppenheimer comments, "Typical of past corrections, in July, LLTC was one of...

Oppenheimer & Co. is out with a research report on RRsat Global Communications Networks Ltd. (NASDAQ: RRST) and it has a Perform rating on shares. In a note to clients, Oppenheimer & Co. writes, "First the positives: revenues beat expectations; 2011 guidance was raised again; and a new...

Oppenheimer & Co. is out with a research report on Netease.com Inc. (NASDAQ: NTES) and it has an Outperform rating and a $60 price target on shares. In a note to clients, Oppenheimer & Co. writes, "NTES reported 3Q11 results that were significantly above expectations. Gross margin remained...

Oppenheimer & Co. is out with a research report on NetApp, Inc. (NASDAQ: NTAP) and it has a Perform rating on shares after it reported earnings. In a note to clients, Oppenheimer & Co. writes, "NetApp delivered disappointing FY2Q12 results with revenues and guidance coming in below...

Oppenheimer & Co. is out with a research report on Vistaprint N.V. (NASDAQ: VPRT) and it has a Perform rating on shares. In a note to clients, Oppenheimer & Co. writes, "Following Vistaprint's F1Q (Sept.) results, we are increasing our F12 non-GAAP EPS forecast to reflect share repurchases...

Oppenheimer & Co. is out with a research report on Simcere Pharmaceutical Group (NASDAQ: SPAR) and it has a Perform rating. In a note to clients, Oppenheimer & Co. writes, "SCR reported an 8.9% yoy sales decline due to under-performance of Edaravone and "other branded generics" (-20%yoy),...

Oppenheimer & Co. is out with a research report on AEterna Zentaris Inc. (NASDAQ: AEZS) and it has an Outperform rating and a $5 price target on shares. In a note to clients, Oppenheimer & Co. writes, "Earlier today AEZS reported financial results for 3Q11 and provided an update on its...

Oppenheimer & Co. is out with a research report on Mindray Medical Int'l Ltd. (NYSE: MR) and it has an Outperform rating and a $32 price target on shares. In a note to clients, Oppenheimer & Co. writes, "MR's 3Q11 revenue growth of 29.8% beat our/Street estimates of 16.7%/18.7% by a wide...